Paraoxonase 1 (PON-1) polymorphisms,activity and Coronary Artery Disease (CAD)

Not Applicable

Completed

• Conditions: Health Condition 1: null- Angiographically proven Coronary Artery Disease patientsHealth Condition 2: I248- Other forms of acute ischemic heart disease

• Registration Number: CTRI/2017/08/009319
• Lead Sponsor: Diamond Jubilee Society Trust King Edward Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-02-06
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 602

Inclusion Criteria

A)For Cases:

1. Males or females aged >=18 years.

2. Patient having any one of the following CAD with at least 50 percent occlusion of the lumen of one or more coronary arteries, as evidenced by coronary angiography, IVUS, or other methods.i.Acute coronary syndrome (STEMI / NSTEMI/ Unstable angina)ii.Chronic stable angina.

3. Patient willing to give written informed consent.

B)For Controls:

1. Normal and healthy individual of either gender between 18 to 65 years, both inclusive.

2. No history of major illness in the past 6 months and should not be taking any kind of medication at least 4 weeks prior to participation in the trial.

3.The volunteer willing to abide by trial procedures and give written informed consent

Exclusion Criteria

A)For Cases:

1.Any medical or psychiatric condition which in the opinion of the investigator makes the patient an unsuitable candidate for the study

2. The participant in any other investigational study in last 4 weeks

3. History of alcohol or substance abuse within the past year

For Controls:

1. Clinically significant haematological and biochemical parameters as assessed by the investigator

2. Pregnant and lactating women.

3. Volunteers having signs and symptoms of AIDS and/or advanced Hepatitis B infection.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To study the prevalence ofGln-Arg192 (Q192R) and Leu-Met55 (L55M) polymorphisms of PON-1 in normal healthy volunteers[Controls] and patients of Coronary Artery Disease (CAD) [Cases]Timepoint: 1 year

Secondary Outcome Measures

Name	Time	Method
To compare PON-1 activity between cases and controlsTimepoint: 1 year;To evaluate the association of PON-1 polymorphisms and CAD.Timepoint: 1 year